Show simple item record

dc.contributor.authorHenderson, DRen_US
dc.contributor.authorMurray, JRen_US
dc.contributor.authorGulliford, SLen_US
dc.contributor.authorTree, ACen_US
dc.contributor.authorHarrington, KJen_US
dc.contributor.authorVan As, NJen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-07-04T13:08:53Z
dc.date.issued2018-09en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29807801en_US
dc.identifierS0936-6555(18)30242-5en_US
dc.identifier.citationClin Oncol (R Coll Radiol), 2018, 30 (9), pp. 539 - 547en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1978
dc.identifier.eissn1433-2981en_US
dc.identifier.doi10.1016/j.clon.2018.05.001en_US
dc.description.abstractAIMS: There are limited data on dosimetric correlates of toxicity in stereotactic body radiotherapy (SBRT) for prostate cancer. We aimed to identify potential relationships between dose and toxicity using conventional dose-volume histograms (DVHs) and dose-surface maps (DSMs). MATERIALS AND METHODS: Urinary bladder trigone and rectum DSMs were produced for a single-institution service evaluation cohort of 50 patients receiving SBRT for localised prostate cancer, together with conventional DVHs for bladder and rectum. Patients had been prospectively recruited to this cohort and treated according to a pre-defined protocol to a dose of 36.25 Gy in five fractions. Radiation Therapy Oncology Group (RTOG) and International Prostate Symptom Score (IPSS) toxicity data were recorded prospectively. Logistic regression was used to identify dosimetric predictors of acute IPSS+10 (rise of 10 points or more above baseline) and grade 2+ RTOG toxicity. RESULTS: On univariate analysis, trigone area receiving 40 Gy and trigone Dmax were associated with IPSS+10 (odds ratio 1.06 [1.02-1.11], P = 0.007 and odds ratio 1.54 [1.06-2.25], P = 0.024, respectively). These two variables were highly correlated. In a multivariate model, including all baseline variables, trigone Dmax remained associated with IPSS+10 (odds ratio 1.91 [1.13-3.22], P = 0.016). These findings were not significant with Holm-Bonferroni correction for multiple testing (corrected P value threshold 0.006). No associations were seen between rectal toxicity and DVH or DSM parameters. CONCLUSIONS: Our study suggests a potential relationship between high doses to the urinary bladder trigone and patient-reported urinary toxicity in prostate SBRT, and is consistent with previous studies in conventionally fractionated radiotherapy, justifying further evaluation in larger cohorts.en_US
dc.format.extent539 - 547en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectProstateen_US
dc.subjectradiotherapyen_US
dc.subjectrectumen_US
dc.subjectstereotacticen_US
dc.subjecttoxicityen_US
dc.subjecttrigoneen_US
dc.titleAn Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-04-13en_US
rioxxterms.versionofrecord10.1016/j.clon.2018.05.001en_US
rioxxterms.licenseref.startdate2018-09en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClin Oncol (R Coll Radiol)en_US
pubs.issue9en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiotherapy Physics Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume30en_US
pubs.embargo.termsNot knownen_US
icr.researchteamRadiotherapy Physics Modellingen_US
icr.researchteamStereotactic and Precision Body Radiotherapyen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen_US
dc.contributor.icrauthorGulliford, Sarahen_US
dc.contributor.icrauthorvan As, Nicken_US
dc.contributor.icrauthorTree, Alisonen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record